Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Mullard

Showing results (61-70 of 684) with videos related to

Pageof 69
Sort By:
Nature Reviews. Drug Discovery|August 5, 2022
BCMA-targeted bispecific gets first green light, in the EUAsher Mullard
Lancet (London, England)|June 8, 2020
COVID-19 vaccine development pipeline gears upAsher Mullard
Nature Reviews. Drug Discovery|June 10, 2020
Targeted degraders clear first safety hurdlesAsher Mullard
Nature Reviews. Drug Discovery|August 14, 2021
What's next for an immuno-oncology powerhouse?Asher Mullard
Nature Reviews. Drug Discovery|December 2, 2022
FDA approves anti-CD3 antibody to delay type 1 diabetes onsetAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
FDA approves fifth RNAi drug - Alnylam's next-gen hATTR treatmentAsher Mullard
Nature Reviews. Drug Discovery|January 10, 2023
GPRC5D-targeted bispecific bolsters T-cell-engager pipelineAsher Mullard
Nature Reviews. Drug Discovery|January 23, 2023
The KRAS crowd targets its next cancer mutationsAsher Mullard
Nature Reviews. Drug Discovery|May 20, 2022
Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimeticsAsher Mullard
Nature Reviews. Drug Discovery|May 10, 2022
Pull incentives for antibiotics get push from the UKAsher Mullard
Pageof 69

Showing results (61-70 of 684) with videos related to

Sort By:
Pageof 69
Nature Reviews. Drug Discovery|August 5, 2022
BCMA-targeted bispecific gets first green light, in the EUAsher Mullard
Lancet (London, England)|June 8, 2020
COVID-19 vaccine development pipeline gears upAsher Mullard
Nature Reviews. Drug Discovery|June 10, 2020
Targeted degraders clear first safety hurdlesAsher Mullard
Nature Reviews. Drug Discovery|August 14, 2021
What's next for an immuno-oncology powerhouse?Asher Mullard
Nature Reviews. Drug Discovery|December 2, 2022
FDA approves anti-CD3 antibody to delay type 1 diabetes onsetAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
FDA approves fifth RNAi drug - Alnylam's next-gen hATTR treatmentAsher Mullard
Nature Reviews. Drug Discovery|January 10, 2023
GPRC5D-targeted bispecific bolsters T-cell-engager pipelineAsher Mullard
Nature Reviews. Drug Discovery|January 23, 2023
The KRAS crowd targets its next cancer mutationsAsher Mullard
Nature Reviews. Drug Discovery|May 20, 2022
Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimeticsAsher Mullard
Nature Reviews. Drug Discovery|May 10, 2022
Pull incentives for antibiotics get push from the UKAsher Mullard
Pageof 69